Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Access to innovative kidney treatments. H.R.5074 - Protecting Young Minds Online Act, S.4510 - Kidney PATIENT Act of 2024. Pharmaceutical pricing proposals, Medicare pharmaceutical payment and access issues. Coverage of oral only End-Stage Renal Disease drugs.
Access to innovative kidney treatments. H.R.5074 - Protecting Young Minds Online Act, S.4510 - Kidney PATIENT Act of 2024. Pharmaceutical pricing proposals, Medicare pharmaceutical payment and access issues. Coverage of oral only End-Stage Renal Disease drugs.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ARDELYX, INC. via ARDELYX, INC.
2026 · third_quarter · Q3
Access, pricing and reimbursement; drug pricing issues; Medicare ESRD pharmaceutical access and reimbursement issues; ESRD benefit
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ARDELYX, INC. via ARDELYX, INC.
2026 · second_quarter · 2A
Source: Senate LDA
H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
Access to innovative medications for people with kidney failure; reimbursement; drug pricing; most favored nation drug pricing; Medicare kidney care access and payment issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ARDELYX, INC. via ARDELYX, INC.
2026 · second_quarter · Q2
Access to innovative medications for people with kidney failure; reimbursement; drug pricing; most favored nation drug pricing; Medicare kidney care access and payment issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ARDELYX, INC. via ARDELYX, INC.
2026 · first_quarter · Q1
Access to innovative kidney treatments, ESRD PPS, coverage of oral only medications for people with ESRD, innovation, Drug pricing, Medicare access to pharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ARDELYX, INC. via ARDELYX, INC.
2025 · third_quarter · Q3
Access to innovative kidney treatments. H.R.5074 - Protecting Young Minds Online Act, S.4510 - Kidney PATIENT Act of 2024. Pharmaceutical pricing proposals, Medicare pharmaceutical payment and access issues. Coverage of oral only End-Stage Renal Disease drugs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ARDELYX, INC. via ARDELYX, INC.
2025 · second_quarter · Q2
Medicaid rebate, most favored nation drug pricing. Increase Access to Innovation for People with Kidney Failure. Support Medicare Part D access to phosphorus-lowering medications.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
ARDELYX, INC. via ARDELYX, INC.
2024 · fourth_quarter · Q4
H.R.5074 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 - To delay incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. S.4510 - A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE